He, Q.; Bu, F.; Zhang, H.; Wang, Q.; Tang, Z.; Yuan, J.; Lin, H.-S.; Xiang, X.
Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. Pharmaceuticals 2021, 14, 198.
https://doi.org/10.3390/ph14030198
AMA Style
He Q, Bu F, Zhang H, Wang Q, Tang Z, Yuan J, Lin H-S, Xiang X.
Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. Pharmaceuticals. 2021; 14(3):198.
https://doi.org/10.3390/ph14030198
Chicago/Turabian Style
He, Qingfeng, Fengjiao Bu, Hongyan Zhang, Qizhen Wang, Zhijia Tang, Jing Yuan, Hai-Shu Lin, and Xiaoqiang Xiang.
2021. "Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling" Pharmaceuticals 14, no. 3: 198.
https://doi.org/10.3390/ph14030198
APA Style
He, Q., Bu, F., Zhang, H., Wang, Q., Tang, Z., Yuan, J., Lin, H. -S., & Xiang, X.
(2021). Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. Pharmaceuticals, 14(3), 198.
https://doi.org/10.3390/ph14030198